All eyes on Supreme Court as it weighs Myriad's gene patents

In August, Myriad Genetics ($MYGN) won an appeals court affirmation of its rights to patent isolated genes related to cancer, but today the Supreme Court will take up the issue of whether intellectual property stretches all the way to the genetic code. Opponents argue that the patents give Myriad a monopoly in certain diagnostic testing markets, unfairly allowing the company to capitalize on what is part of the human body. Meanwhile, industry supporters caution that nullifying Myriad's patents would severely hamstring a beneficial wing of scientific research. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.